Literature DB >> 21222181

Which combination therapy is superior at reducing cardiovascular events in diabetic patients with hypertension?

Charles T Upchurch1, Eugene J Barrett.   

Abstract

Entities:  

Year:  2011        PMID： 21222181     DOI： 10.1007/s11892-011-0177-z

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  4 in total

1.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

2.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Authors:  Kenneth Jamerson; Michael A Weber; George L Bakris; Björn Dahlöf; Bertram Pitt; Victor Shi; Allen Hester; Jitendra Gupte; Marjorie Gatlin; Eric J Velazquez
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

3.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

Review 4.  Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.

Authors:  Kenneth A Jamerson; George L Bakris; Chuan-Chuan Wun; Björn Dahlöf; Martin Lefkowitz; Sheryl Manfreda; Bertram Pitt; Eric J Velazquez; Michael A Weber
Journal:  Am J Hypertens       Date:  2004-09       Impact factor: 2.689
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.